Landscape of CDKN1B mutations in luminal breast cancer and other Hormone-Driven Human Tumors

Martina Cusan, Giorgia Mungo, Mara De Marco Zompit, Ilenia Segatto, Barbara Belletti, Gustavo Baldassarre

Research output: Contribution to journalReview articlepeer-review

Abstract

The CDKN1B gene encodes for the p27Kip1 protein, firstly characterized as a cyclin dependent kinase (CDK)-inhibitor. Germline CDKN1B pathogenic variants have been described in hereditary tumors, such as multiple endocrine neoplasia (MEN)-like syndromes and familial prostate cancer. Despite its central role in tumor progression, for a long time it has been proposed that CDKN1B was very rarely somatically mutated in human cancer and that its expression levels were almost exclusively regulated at post-transcriptional level. Yet, the advent of massive parallel sequencing has partially subverted this general understanding demonstrating that, at least in some types of cancer, CDKN1B is mutated in a significant percentage of analyzed samples. Recent works have demonstrated that CDKN1B can be genetically inactivated and this occurs particularly in sporadic luminal breast cancer, prostate cancer and small intestine neuroendocrine tumors. However, a clear picture of the extent and significance of CDKN1B mutations in human malignances is still lacking. To fill this gap, we interrogated the COSMIC, ICGC, cBioPortal, and TRANSFAC data portals and current literature in PubMed, and reviewed the mutational spectrum of CDKN1B in human cancers, interpreting the possible impact of these mutations on p27Kip1 protein function and tumor onset and progression.

Original languageEnglish
Article number393
JournalFrontiers in Endocrinology
Volume9
Issue numberJUL
DOIs
Publication statusPublished - Jul 17 2018

Keywords

  • CDKN1B gene
  • Driver mutation
  • Germinal mutation
  • Intrinsically disordered protein/region
  • p27 protein
  • Passenger mutation
  • Somatic mutation

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Fingerprint

Dive into the research topics of 'Landscape of CDKN1B mutations in luminal breast cancer and other Hormone-Driven Human Tumors'. Together they form a unique fingerprint.

Cite this